Guy-Charles Fanneau de la Horie
Director/Board Member bei GENFLOW BIOSCIENCES PLC
Vermögen: 5 589 $ am 31.03.2024
Profil
Guy-Charles Fanneau de la Horie is an Independent Non-Executive Director at Genflow Biosciences Plc and a Member-Supervisory Board at Pharnext SA. He previously served as the Chief Executive Officer & Director at Neovacs SA from 2011 to 2013, was the Chief Executive Officer at PathoQuest SAS, served as the Chairman-Executive Board at Pherecydes Pharma SA from 2016 to 2022, and was a Director at Nanobiotix SA. He holds an MBA degree from INSEAD, which he received in 1988.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GENFLOW BIOSCIENCES PLC
0,10% | 31.12.2022 | 300 000 ( 0,10% ) | 5 589 $ | 31.03.2024 |
Aktive Positionen von Guy-Charles Fanneau de la Horie
| Unternehmen | Position | Beginn |
|---|---|---|
| GENFLOW BIOSCIENCES PLC | Director/Board Member | 29.06.2022 |
| PHARNEXT SCA | Director/Board Member | 10.07.2023 |
Ehemalige bekannte Positionen von Guy-Charles Fanneau de la Horie
| Unternehmen | Position | Ende |
|---|---|---|
| PHERECYDES PHARMA | Chief Executive Officer | 19.05.2022 |
| NEOVACS | Chief Executive Officer | 17.10.2013 |
PathoQuest SAS
 PathoQuest SAS Medical SpecialtiesHealth Technology PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France. | Chief Executive Officer | - |
| NANOBIOTIX | Director/Board Member | - |
Ausbildung von Guy-Charles Fanneau de la Horie
| INSEAD | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| NEOVACS | Health Technology |
| NANOBIOTIX | Health Technology |
| PHARNEXT SCA | Health Technology |
| GENFLOW BIOSCIENCES PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
PathoQuest SAS
PathoQuest SAS Medical SpecialtiesHealth Technology PathoQuest SAS provides diagnostic development services for cancer and infectious diseases. Its services include viral safety testing, adventitious virus detection in cell lines under development and in Master Cell Banks, adventitious virus detection in viral stocks, and identify of the sequences of murine sarcoma virus. The company was founded by Luc Boblet and Marc Eloit on September 14, 2010 and is headquartered in Paris, France. | Health Technology |
Pherecydes Pharma SA
 Pherecydes Pharma SA Pharmaceuticals: MajorHealth Technology Pherecydes Pharma SA is a biotechnology company, which engages in the research and development of anti-infective therapies based on the use of bacteriophages. It develops phage treatments of bacterial infections. The company was founded by Jerome Gabard and Manuel Gea in December 2006 and is headquartered in Romainville, France. | Health Technology |
